Sanofi in millions of deal with EVOQ

Image Credit: Business Standard

Announcement 

Sanofi is making headlines with another autoimmune pact by joining Chicago’s EVOQ Therapeutics for its exclusive technology that focuses on restoring the natural immune tolerance in the body. The partners are yet to reveal their primary indications. The companies have not availed its of a detailed breakdown of the agreement's financial terms. On Thursday, they only mentioned their overall total consideration could be around $500 million. This sum amount will include preclinical and upfront payment, sales and development profit. Alongside EVOQ will be counted for tiered royalties on the sales of the products.

Key highlights of this partnership

The centre of attraction in this collaboration is EVOQ’s exclusive nanodisc platform. This platform allows the specific elements with a focus on dendritic cells. This is a type of immune cell that claims to be a major player in immune tolerance. The autoimmune disease patients in dendritic cells adversely activate the cell-mediated immune reaction that causes specific organs and tissues to by default address a foreign.

Following the excellence of EVOQ’s platform, Sanofi has entered into a partnership. Sanofi has been largely investing in autoimmune diseases this year. The company's press announcement states that the nanodisc idea can effectively come up in favour of curative treatments for autoimmune diseases like type 1 diabetes and celiac disease. Anyway, the partners have not yet encountered a particular indication to concentrate on by now. As per the terms of the agreement, the companies will together indulge in research activities, with Sanofi taking responsibility for commercialisation and development tasks globally.

Sanofi’s constant financial efforts towards autoimmune and more

Around March, to obtain Dren Bio’s bispecific antibody DR-0201, the pharma invested $1.9 billion on the line with $1.3 billion in launch and development and $600 million in an upfront payment. After a few weeks, Sanofi invested $125 million and promised $1.72 billion in commercial and development profit, under the license agreement of two bispecific antibodies from Earendil Labs. Following the development of inflammatory and autoimmune bowel disease.

In June, Sanofi thought of moving ahead with one preclinical molecular glue asset found during its latest Kymera partner. The companies partnered in July 2020 with a worth $150 million and committed $2 billion in profit in a protein degrader program targeting immune-inflammatory conditions. Apart from the immunology area, Sanofi obtained a UK UK-related startup, vicebio, for a worth $1.6 billion.